Butterfly Network

Butterfly Network has signed a multi-year license agreement with Merge Labs that gives Merge access to the Poseidon family of Ultrasound-on-Chip technology through Butterfly Embedded, Butterfly’s licensing business. Merge Labs plans to use the semiconductor-based ultrasound platform to develop ultrasound-enabled brain-computer interfaces. The agreement includes upfront and milestone payments, hardware purchase commitments, and ongoing royalties on future revenues; Butterfly will be the exclusive partner for Merge’s CMOS‑MEMS chip‑based ultrasound technology but reserves the right to grant additional licenses. » Więcej na de.investing.com

The stock of Butterfly Network rose to a 52-week high of $9.74 and is currently trading around $9.77, implying a market capitalization of about $2.57 billion and a 1-year performance of +601.47%. Data from InvestingPro view the stock as significantly above its fair value and point to a high beta of 2.08, indicating considerable volatility. In Q2 2026 the company reported adjusted EPS of -$0.01 (better than expected) on revenue of $15.72 million (below expectations), but raised its full-year outlook and highlighted a record quarter with stronger margins and higher US sales. » Więcej na de.investing.com

Butterfly Network replaces traditional ultrasound crystals with a low-cost silicon microchip, transforming medical imaging. The company is shifting from a hardware provider to a platform, with cloud and AI software revenues already making up more than 40% of sales. A planned push into at-home patient monitoring from late 2026 is expected to open large future markets, but the stock remains speculative. » Więcej na finanzen.net